The efficacy and safety of wedge resection for peripheral stage IA lung adenocarcinoma: a real-world study based on a single center

被引:3
|
作者
Bian, Dongliang [1 ]
Xiong, Yicheng [1 ]
Jin, Kaiqi [1 ]
Zhu, Yuming [1 ]
Yu, Huansha [2 ]
Dai, Jie [1 ]
Jiang, Gening [1 ]
机构
[1] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Thorac Surg, Shanghai, Peoples R China
[2] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Anim Expt Ctr, Shanghai, Peoples R China
基金
中国国家自然科学基金; 国家重点研发计划;
关键词
Lung adenocarcinoma stage IA; wedge resection; recurrence; SECTION COMPUTED-TOMOGRAPHY; LIMITED RESECTION; SUBLOBAR RESECTION; SURVIVAL OUTCOMES; CANCER; LOBECTOMY; IMPACT; CLASSIFICATION;
D O I
10.21037/jtd-22-1010
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: The effectiveness of segmentectomy for stage IA lung adenocarcinoma (IA-LUAD) has been well-documented. However, the efficacy and safety of wedge resection for peripheral IA-LUAD remains controversial. This study evaluated the feasibility of wedge resection in patients with peripheral IA-LUAD. Methods: Patients with peripheral IA- LUAD who underwent wedge resection by video- assisted thoracoscopic surgery (VATS) at Shanghai Pulmonary Hospital were reviewed. Cox proportional hazards modeling was performed to identify predictors of recurrence. Receiver operating characteristic (ROC) curve analysis was used to calculate the optimal cutoffs of identified predictors. Results: A total of 186 patients (female/male, 115/ 71; mean age, 59.9 years) were included. Mean maximum dimension of consolidation component (MCD) was 5.6 mm, consolidation-to-tumor ratio (CTR) was 37%, and mean computed tomography value of tumor (CTVt) was -285.4 HU. With a median follow-up of 67 months (interquartile range, 52-72 months), the 5-year recurrence rate was 4.84%. Ten patients occurred recurrence postoperatively. No recurrence was observed adjacent to the surgical margin. Increasing MCD, CTR, and CTVt were associated with a higher risk of recurrence, with corresponding hazard ratios (HRs) of 1.212 [95% confidence interval (CI): 1.120-1.311], 1.054 (95% CI: 1.018-1.092), and 1.012 (95% CI: 1.004-1.019) with optimal cutoffs for predicting recurrence of 10 mm, 60%, and -220 HU, respectively. When a tumor had characteristics under these respective cutoffs, no recurrence was observed. Conclusions: Wedge resection can be considered to be a safe and efficacious management strategy for patients with peripheral IA-LUAD, especially for MCD less than 10 mm, CTR less than 60% and CTVt less than -220 HU.
引用
收藏
页码:54 / 64
页数:11
相关论文
共 50 条
  • [1] Real-world outcomes of lobectomy, segmentectomy and wedge resection for the treatment of stage c-IA lung carcinoma
    Thomas, Pascal Alexandre
    Seguin-Givelet, Agathe
    Pages, Pierre-Benoit
    Alifano, Marco
    Brouchet, Laurent
    Falcoz, Pierre-Emmanuel
    Baste, Jean-Marc
    Glorion, Matthieu
    Belaroussi, Yaniss
    Filaire, Marc
    Heyndrickx, Maxime
    Loundou, Anderson
    Fourdrain, Alex
    Dahan, Marcel
    Boyer, Laurent
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2024, 66 (01)
  • [2] Segmentectomy Versus Wedge Resection for Stage IA Lung Adenocarcinoma-A Population-Based Study
    Chiang, Xu-Heng
    Wei, Chih-Fu
    Lin, Ching-Chun
    Lin, Mong-Wei
    Chiang, Chun-Ju
    Lee, Wen-Chung
    Chen, Jin-Shing
    Chen, Pau-Chung
    CANCERS, 2025, 17 (06)
  • [3] Limited resection for stage IA radiologically invasive lung cancer: a real-world nationwide database study
    Soh, Junichi
    Toyooka, Shinichi
    Shintani, Yasushi
    Okami, Jiro
    Ito, Hiroyuki
    Ohtsuka, Takashi
    Morig, Takeshi
    Watanabe, Shun-Ichi
    Asamura, Hisao
    Chida, Masayuki
    Endo, Shunsuke
    Nakanishi, Ryoichi
    Kadokure, Mitsutaka
    Suzuki, Hidemi
    Miyaoka, Etsuo
    Yoshinon, Ichiro
    Date, And Hiroshi
    EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 2022, 62 (01)
  • [4] Segmentectomy or Wedge Resection in Stage IA Lung Squamous Cell Carcinoma and Adenocarcinoma?
    Li, Guoshu
    Xie, Shuanshuan
    Hu, Feng
    Tan, Min
    Fan, Lihong
    Wang, Changhui
    JOURNAL OF CANCER, 2021, 12 (06): : 1708 - 1714
  • [5] Clinical efficacy and safety of adjuvant EGFR-TKIs for resected stage IB lung adenocarcinoma: A real-world study based on propensity score matching
    Shen, Leilei
    Guo, Juntang
    Zhang, Weidong
    Zhang, Lianbin
    Liu, Xi
    Wang, Tao
    Zhang, Tao
    Liang, Chaoyang
    Liu, Yang
    CANCER MEDICINE, 2023, 12 (18): : 18470 - 18478
  • [6] Efficacy and Safety of Sesame Oral Immunotherapy-A Real-World, Single-Center Study
    Nachshon, Liat
    Goldberg, Michael R.
    Levy, Michael B.
    Appel, Michael Y.
    Epstein-Rigbi, Naama
    Lidholm, Jonas
    Holmqvist, Marie
    Katz, Yitzhak
    Elizur, Arnon
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2019, 7 (08): : 2775 - +
  • [7] Efficacy and Safety of Nintedanib and Docetaxel in Patients with Lung Adenocarcinoma: A Multicenter Real-world Analysis
    Jakopovic, M.
    Ljubicic, L.
    Janzic, U.
    Unk, M.
    Terglav, A. S.
    Mohorcic, K.
    Seiwerth, F.
    Bitar, L.
    Badovinac, S.
    Plestina, S.
    Samarzija, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S607 - S607
  • [8] Efficacy and safety of telitacicept in patients with lupus nephritis: a single-center, real-world retrospective study
    Huang, Xiaolu
    Lin, Fuan
    Chen, Hongpu
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2024, 28 (09) : 902 - 909
  • [9] Early Real-World Safety, Tolerability, and Efficacy of Cladribine Tablets: A Single Center Experience
    Bain, Julie
    Jones, Ashley
    Overholt, Sarah
    Guenette, Melanie
    Selchen, Daniel
    Oh, Jiwon
    NEUROLOGY, 2020, 94 (15)
  • [10] Early real-world safety, tolerability, and efficacy of cladribine tablets: a single center experience
    Bain, J.
    Oh, J.
    Jones, A.
    Selchen, D.
    Overholt, S.
    Guenette, M.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 274 - 274